Barclays PLC Boosts Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)

Barclays PLC increased its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 140.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 60,014 shares of the company’s stock after buying an additional 35,022 shares during the quarter. Barclays PLC’s holdings in Keros Therapeutics were worth $3,484,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. KBC Group NV increased its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after buying an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. acquired a new stake in shares of Keros Therapeutics in the third quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics during the second quarter valued at $128,000. Finally, LMR Partners LLP acquired a new position in Keros Therapeutics during the third quarter valued at $213,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Stock Performance

KROS opened at $17.12 on Tuesday. Keros Therapeutics, Inc. has a one year low of $15.67 and a one year high of $73.00. The stock has a market capitalization of $693.48 million, a P/E ratio of -3.29 and a beta of 1.20. The business’s 50-day simple moving average is $54.97 and its 200-day simple moving average is $51.62.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue was up 4750.0% on a year-over-year basis. During the same period last year, the firm earned ($1.33) earnings per share. On average, equities research analysts forecast that Keros Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wedbush reissued an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. Bank of America decreased their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Scotiabank decreased their target price on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a research note on Friday, December 13th. Finally, TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, Keros Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $75.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.